Vulvar Cancer - Pipeline Review, H1 2018

  • ID: 4540607
  • Report
  • 125 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Cutanea Life Sciences Inc
  • IRX Therapeutics Inc
  • ISA Pharmaceuticals BV
  • MedImmune LLC
  • Merck KGaA
  • MORE
Vulvar Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H1 2018, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN), or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

Report Highlights:

This latest pipeline guide Vulvar Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 7 and 2 respectively.

Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb Co
  • Cutanea Life Sciences Inc
  • IRX Therapeutics Inc
  • ISA Pharmaceuticals BV
  • MedImmune LLC
  • Merck KGaA
  • MORE
Introduction

Report Coverage

Vulvar Cancer - Overview

Vulvar Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vulvar Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vulvar Cancer - Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Cutanea Life Sciences Inc

IRX Therapeutics Inc

ISA Pharmaceuticals BV

MedImmune LLC

Merck KGaA

Ono Pharmaceutical Co Ltd

Transgene SA

Vulvar Cancer - Drug Profiles

ABI-1968 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab + tremelimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IRX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ISA-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-7824 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

Mechanism Of Action

R&D Progress

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vulvar Cancer - Dormant Projects

Vulvar Cancer - Product Development Milestones

Featured News & Press Releases

Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP

Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine

Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials

Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Vulvar Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Vulvar Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H1 2018

Vulvar Cancer - Pipeline by IRX Therapeutics Inc, H1 2018

Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2018

Vulvar Cancer - Pipeline by MedImmune LLC, H1 2018

Vulvar Cancer - Pipeline by Merck KGaA, H1 2018

Vulvar Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Vulvar Cancer - Pipeline by Transgene SA, H1 2018

Vulvar Cancer - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Vulvar Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bristol-Myers Squibb Co
  • Cutanea Life Sciences Inc
  • IRX Therapeutics Inc
  • ISA Pharmaceuticals BV
  • MedImmune LLC
  • Merck KGaA
  • Ono Pharmaceutical Co Ltd
  • Transgene SA
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll